Kwality Pharmaceuticals Reports Strong Financial Growth and Improved Profitability in March 2025 Results

Kwality Pharmaceuticals has reported its financial results for the quarter ending March 2025, showcasing a range of positive developments. The company's score has undergone an adjustment in evaluation, reflecting a notable shift from 9 to 19 over the past three months. The financial data reveals several key highlights for Kwality Pharma. The operating profit to interest ratio has reached its highest level at 10.40 times, indicating an enhanced capacity to manage interest payments effectively. Additionally, profit before tax less other income (PBT) has shown significant growth, reported at Rs 18.30 crore, marking a year-on-year increase of 46.40%. Similarly, profit after tax (PAT) has also demonstrated strong performance, recorded at Rs 14.49 crore, with a year-on-year growth of 54.4%. Net sales have reached Rs 115.68 crore, the highest in the last five quarters, reflecting a year-on-year growth of 25.77%. Operating profit (PBDIT) has also peaked at Rs 25.90 crore, further underscoring the company's positive financial trajectory. Earnings per share (EPS) have reached Rs 13.96, indicating an increase in profitability and enhanced returns for shareholders. For more insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.